Literature DB >> 8939281

Full-information models for multiple psychometric tests: annualized rates of change in normal aging and dementia.

R McCleary1, M B Dick, G Buckwalter, V Henderson, W R Shankle.   

Abstract

The rates of change for five widely used psychometric tests were analyzed to compare how much more variance reduction can be achieved using full-information methods relative to the single-equation methods previously used in dementia research. Nondemented controls and subjects with Alzheimer disease (AD), probable/ possible vascular dementia (VD), or mixed dementia (MD) were evaluated. A cohort design was followed, with follow-up of three demented groups and one normal control group; data were analyzed in a multiple-equation regression model estimated with full-information methods. The study was conducted at Alzheimer's Disease Research Center sites at the University of California, Irvine, and at the University of Southern California. In all, 226 patients and controls who had completed initial assessment and at least one annual reassessment were included in the study. Dependent variables were annualized rates of change in the Mini-Mental State Examination (MMSE), the Short-Blessed Dementia Rating Scale (DRS), the Consortium to Establish a Registry for Alzheimer's Disease drawings test (CD), the WAIS-R Block Design test (WRB), and the Boston Naming Test (BNT). Independent variables were dementia severity, diagnosis (AD, VD, MD, or control), sex, age, marital status, education, and age at onset. Full-information methods reduced the variance in the change scores by > or = 25% compared with previous studies. The model's prediction of a test's rate of change was almost entirely due to dementia stage and diagnosis. The effects of other explanatory variables (sex, marital status, age, and education) were weak and statistically insignificant. When the effects of other independent variables were controlled, AD and MD patients were found to decline at significantly faster rates than VD patients. Full-information methods, relative to single-equation methods, substantially reduce the variance of rates of change for multiple psychometric tests. They do so by simultaneously considering the correlated error terms in the regression for each dependent psychometric change score variable. The robustness of these results to minor variations in follow-up time suggests that annualization is a reasonably valid procedure for making change scores comparable. This study's results suggest that change scores in psychometric tests provide information that can be used to aid differential diagnosis. However, the large variances of change scores preclude many other uses. Finally, since standardization of psychometric change scores translates all tests to the same scale (0-100%), standardized change scores are easier to interpret. The analysis of standardized change scores deserves further investigation.

Entities:  

Mesh:

Year:  1996        PMID: 8939281     DOI: 10.1097/00002093-199601040-00007

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  3 in total

1.  Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis.

Authors:  Zhong-Zheng Zhu; Lifang Hou; Valentina Bollati; Letizia Tarantini; Barbara Marinelli; Laura Cantone; Allen S Yang; Pantel Vokonas; Jolanta Lissowska; Silvia Fustinoni; Angela C Pesatori; Matteo Bonzini; Pietro Apostoli; Giovanni Costa; Pier Alberto Bertazzi; Wong-Ho Chow; Joel Schwartz; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2010-09-15       Impact factor: 7.196

2.  Frequent assessments may obscure cognitive decline.

Authors:  Timothy A Salthouse
Journal:  Psychol Assess       Date:  2014-05-19

3.  Intelligent Algorithm-Based Quantitative Electroencephalography in Evaluating Cerebral Small Vessel Disease Complicated by Cognitive Impairment.

Authors:  Hengya Zhu; Jingjing Qiu; Xiaoyan Sun; Xiangyan Yang; Bin Zhang; Ying Tan
Journal:  Comput Math Methods Med       Date:  2022-01-29       Impact factor: 2.238

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.